Coloplast A/S (OTCMKTS:CLPBY) Upgraded by Sanford C. Bernstein to “Strong-Buy” Rating

Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBYFree Report) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Several other brokerages also recently commented on CLPBY. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res upgraded shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.

Check Out Our Latest Research Report on Coloplast A/S

Coloplast A/S Price Performance

Shares of Coloplast A/S stock opened at $11.70 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The stock’s fifty day moving average is $11.52 and its 200 day moving average is $12.60. Coloplast A/S has a one year low of $10.63 and a one year high of $14.34.

Coloplast A/S (OTCMKTS:CLPBYGet Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.08 EPS for the quarter. The firm had revenue of $1.02 billion for the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. On average, equities research analysts forecast that Coloplast A/S will post 0.36 EPS for the current fiscal year.

Coloplast A/S Increases Dividend

The company also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were issued a dividend of $0.2435 per share. The ex-dividend date of this dividend was Monday, December 9th. This is a boost from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio (DPR) is currently 93.94%.

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.

Featured Articles

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.